Prelude Therapeutics Incorporated beat EPS estimates 100% of the time across 16 reported quarters (16 beats, 0 misses), averaging +16.4% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.17 | $-0.14 | +17.6% | Beat | |
| Q1 FY26 | $-0.27 | $-0.13 | +51.9% | Beat | |
| Q4 FY25 | $-0.33 | $-0.20 | +39.4% | Beat | |
| Q3 FY25 | $-0.35 | $-0.26 | +25.7% | Beat | |
| Q2 FY25 | $-0.45 | $-0.41 | +8.9% | Beat | |
| Q1 FY25 | $-0.47 | $-0.42 | +10.6% | Beat | |
| Q4 FY24 | $-0.49 | $-0.38 | +22.4% | Beat | |
| Q3 FY24 | $-0.48 | $-0.43 | +10.4% | Beat | |
| Q2 FY24 | $-0.46 | $-0.46 | +0.0% | Beat | |
| Q1 FY24 | $-0.47 | $-0.42 | +10.6% | Beat | |
| Q4 FY23 | $-0.50 | $-0.47 | +6.0% | Beat | |
| Q3 FY23 | $-0.58 | $-0.45 | +22.4% | Beat |
Back to PRLD overview · PRLD holders · PRLD KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.